Treatment of Pulmonary Neuroendocrine Tumor in Stage I–III Resectable Lung Carcinoid (Typical or Atypical)
Clinical Scenario
This protocol applies to patients with lung carcinoid — either typical or atypical — presenting at UICC TNM stage I, II, or III, where the disease is localised and considered surgically resectable.
Patient Population
Eligible patients have a confirmed pulmonary carcinoid histology (typical or atypical subtype) with localised, resectable disease. The approach may differ based on operative risk and the presence of significant comorbidity. Even in the setting of N2 lymph nodal involvement, surgery remains central to management for this tumour type.
Treatment Approach (Overview)
The protocol centres on a surgical strategy with radical intent for patients who are technically and clinically suitable candidates. For those with significant comorbidity or elevated operative risk, alternative locoregional approaches are considered.
The full protocol — including the complete decision algorithm, patient selection criteria, and management of local recurrence — is available via the link below.
References
DOI: 10.1016/j.annonc.2021.01.003
- Surgery may be carried out upfront after adequate medical preparation in localised resectable tumours resembling LCs or in tumours considered at high risk of bleeding or hormonal crisis or when previous biopsy has failed.
- Surgery represents the treatment of choice for LCs (both TCs and ACs), even in the case of N2 lymph nodal metastases [IV, A].
- In case of local recurrence, surgical resection with radical intent is recommended when technically feasible.
- In patients with significant comorbidity or high operative risk, palliative locoregional procedures or watchful follow-up may constitute an alternative.
View source ↗